IACT
Immunostimulatory Agonist antibodies for Cancer Therapy
| Coordinatore | DEUTSCHES KREBSFORSCHUNGSZENTRUM
Organization address
address: Im Neuenheimer Feld 280 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 8˙227˙907 € |
| EC contributo | 5˙995˙747 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-11-01 - 2017-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Organization address
address: Im Neuenheimer Feld 280 contact info |
DE (HEIDELBERG) | coordinator | 363˙973.00 |
| 2 |
UNIVERSITY OF SOUTHAMPTON
Organization address
address: Highfield contact info |
UK (SOUTHAMPTON) | participant | 1˙295˙820.00 |
| 3 |
RIBOLOGICAL GMBH
Organization address
address: HOLDERLINSTRASSE 8 contact info |
DE (MAINZ) | participant | 1˙096˙400.00 |
| 4 |
UNIVERSITAETSKLINIKUM HEIDELBERG
Organization address
address: IM NEUENHEIMER FELD 672 contact info |
DE (HEIDELBERG) | participant | 981˙860.00 |
| 5 |
LEADARTIS S.L.
Organization address
address: CALLE FERRAZ 3 1 IZQ contact info |
ES (MADRID) | participant | 448˙465.00 |
| 6 |
GLYCOTOPE GMBH
Organization address
address: ROBERT ROSSLE STRASSE 10 contact info |
DE (BERLIN) | participant | 448˙426.00 |
| 7 |
BIOINVENT INTERNATIONAL AB
Organization address
address: Soelvegatan 41 contact info |
SE (LUND) | participant | 448˙399.00 |
| 8 |
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
Organization address
address: Via Venezian 1 contact info |
IT (Milan) | participant | 306˙500.00 |
| 9 |
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Organization address
address: AVENIDA DE PIO XII 55 contact info |
ES (PAMPLONA) | participant | 306˙304.00 |
| 10 |
UNIVERSIDAD DE NAVARRA
Organization address
address: CAMPUS UNIVERSITARIO EDIFICIO CENTRAL contact info |
ES (PAMPLONA) | participant | 299˙600.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immunotherapeutics constitute a clinically effective, marketable drug concept. Ipilimumab is an antagonist immunostimulatory antibody (IS-Ab) that removes the restraint on the immune response by blocking inhibitory receptors on immune cells. Potent immunity can also be elicited by means of agonist IS-Abs that engage activatory receptors. Our program will translate the agonist IS-Ab concept into clinical treatments. This is critical, because a repertoire of complementary drugs that act at different points in the immune regulatory network will be required to counter immune failure in different cancer (sub-)types. Our initiative is supported by longstanding experience as well as by the availability of clinical lead Abs. Pivotal are two clinical trials in which cancer type and treatment regimen have been selected to approximate pre-clinical settings in which striking therapeutic impact with agonist IS-Abs has been obtained. These studies will involve extensive analysis of efficacy-related biomarkers by means of validated assays, not only in blood samples, but also in the most relevant compartment: the tumor microenvironment. While our state-of-the-art agonist IS-Abs are being tested in the clinic, a parallel SME-driven effort will aim at the development of 2nd generation agonist IS-Abs with superior therapeutic index. This innovation is supported by proprietary technology and will result in intellectual property and marketable drugs. Taken together, our interdisciplinary platform is designed to yield maximal benefit for health care, academia and health-related industries in Europe.'